Literature DB >> 32915765

Authors' Reply.

Tadao Akizawa1, Manabu Iwasaki2, Yusuke Yamaguchi3, Yoshikatsu Majikawa4, Michael Reusch5.   

Abstract

Entities:  

Keywords:  chronic kidney disease; erythropoiesis-stimulating agent; hemodialysis; hypoxia-inducible factor; randomized controlled trials

Mesh：

Substances：

Year:  2020        PMID： 32915765      PMCID： PMC7608968          DOI： 10.1681/ASN.2020071096

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  5 in total

1.  Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.

Authors:  Nan Chen; Chuanming Hao; Bi-Cheng Liu; Hongli Lin; Caili Wang; Changying Xing; Xinling Liang; Gengru Jiang; Zhengrong Liu; Xuemei Li; Li Zuo; Laimin Luo; Jianqin Wang; Ming-Hui Zhao; Zhihong Liu; Guang-Yan Cai; Li Hao; Robert Leong; Chunrong Wang; Cameron Liu; Thomas Neff; Lynda Szczech; Kin-Hung P Yu
Journal:  N Engl J Med       Date:  2019-07-24       Impact factor: 91.245

2.  Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.

Authors:  Tadao Akizawa; Manabu Iwasaki; Yusuke Yamaguchi; Yoshikatsu Majikawa; Michael Reusch
Journal:  J Am Soc Nephrol       Date:  2020-06-03       Impact factor: 10.121

3.  Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

Authors:  Robert Provenzano; Anatole Besarab; Steven Wright; Sohan Dua; Steven Zeig; Peter Nguyen; Lona Poole; Khalil G Saikali; Gopal Saha; Stefan Hemmerich; Lynda Szczech; K H Peony Yu; Thomas B Neff
Journal:  Am J Kidney Dis       Date:  2016-02-02       Impact factor: 8.860

4.  The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease.

Authors:  Lucile Mercadal; Lucile Mercadel; Marie Metzger; Jean Philippe Haymann; Eric Thervet; Jean-Jacques Boffa; Martin Flamant; François Vrtovsnik; Pascal Houillier; Marc Froissart; Bénédicte Stengel
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

5.  Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.

Authors:  Nan Chen; Jiaqi Qian; Jianghua Chen; Xueqing Yu; Changlin Mei; Chuanming Hao; Gengru Jiang; Hongli Lin; Xinzhou Zhang; Li Zuo; Qiang He; Ping Fu; Xuemei Li; Dalvin Ni; Stefan Hemmerich; Cameron Liu; Lynda Szczech; Anatole Besarab; Thomas B Neff; Kin-Hung Peony Yu; Frank H Valone
Journal:  Nephrol Dial Transplant       Date:  2017-08-01       Impact factor: 5.992
  5 in total
  1 in total

Review 1.  Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.

Authors:  Mercedes Kile; Patcharaporn Sudchada
Journal:  Int Urol Nephrol       Date:  2020-08-08       Impact factor: 2.370
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.